OVERVIEW
Interstitial lung diseases (ILDs) are a heterogeneous group of diseases characterized by inflammation and/or fibrosis of the lung parenchyma. There are a number of ILDs that may develop a progressive fibrosing phenotype, which is characterized by increased fibrosis on high resolution computed tomography, worsening respiratory symptoms, declining lung function, and early mortality. This interactive live event will provide an update on the definition of progression of pulmonary fibrosis, review the ILDs most likely to develop a progressive fibrosing phenotype, as well as the management and treatment options to slow progression and improve patient outcomes.
GOAL STATEMENT
The goal of this activity is that learners will be better able to recognize and diagnose chronic fibrosing ILDs with a progressive phenotype and initiate timely management of these patients accordingly.
LEARNING OBJECTIVES
Upon completion of this activity, participants will be better able to[list][item]Distinguish types of ILD associated with a risk of developing a progressive fibrosing phenotype[item]Assess factors that reflect progression of ILDs[item]Select the care plan for patients with ILDs with a progressive fibrosing phenotype in the context of a multidisciplinary care team[/list]
ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 0.5 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an independent educational grant from [bold]Boehringer Ingelheim Pharmaceuticals[/bold].